Analyst Reco. Pacira BioSciences, Inc.

Equities

PCRX

US6951271005

Real-time Estimate Cboe BZX Other stock markets 10:12:01 29/04/2024 pm IST			5-day change	1st Jan Change
26.58 ^USD	+0.97%		+1.59%	-21.41%

13/03	Transcript : Pacira BioSciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 01:35 PM
13/03	Pacira BioSciences Says US FDA Granted Knee Osteoarthritis Therapy Candidate RMAT Designation	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

RBC Cuts Price Target on Pacira BioSciences to $45 From $53, Keeps Outperform Rating	01/03	MT
RBC Cuts Price Target on Pacira BioSciences to $53 From $58, Keeps Outperform Rating	03/01	MT
Raymond James Initiates Pacira BioSciences With Outperform Rating, Price Target is $42	20/12	MT
HC Wainwright Adjusts Price Target on Pacira BioSciences to $57 From $63, Maintains Buy Rating	06/11	MT
RBC Cuts Price Target on Pacira BioSciences to $58 From $67, Keeps Outperform Rating	03/11	MT
Barclays Adjusts Pacira BioSciences' Price Target to $57 From $60, Maintains Overweight Rating	23/23/23	MT
Wedbush Lowers Pacira BioSciences' Price Target to $57 From $60, Keeps Outperform Rating	04/23/04	MT
Truist Securities Adjusts Price Target on Pacira BioSciences to $55 From $60, Maintains Buy Rating	03/23/03	MT
TD Cowen Upgrades Pacira BioSciences to Outperform From Market Perform, Price Target is $50	03/23/03	MT
HC Wainwright Adjusts Price Target on Pacira BioSciences to $63 From $68, Maintains Buy Rating	03/23/03	MT
RBC Cuts Price Target on Pacira BioSciences to $68 From $70, Maintains Outperform Rating	03/23/03	MT
Needham Adjusts Price Target on Pacira BioSciences to $52 From $60, Maintains Buy Rating	03/23/03	MT
HC Wainwright Lowers Price Target on Pacira BioSciences to $68 From $71, Maintains Buy Rating	13/23/13	MT
RBC Trims Pacira BioSciences' Price Target to $70 From $72, Keeps Outperform Rating	07/23/07	MT
RBC Cuts Price Target on Pacira BioSciences to $72 From $75, Maintains Outperform Rating	04/23/04	MT
RBC Capital Adjusts Pacira BioSciences Price Target to $75 From $76, Maintains Outperform Rating	06/23/06	MT
RBC Cuts Price Target on Pacira BioSciences to $76 From $80, Maintains Outperform Rating	01/23/01	MT
HC Wainwright Adjusts Price Target on Pacira BioSciences to $71 From $69, Maintains Buy Rating	01/23/01	MT
Wedbush Assumes Pacira BioSciences at Outperform, Cuts Price Target to $60 From $88	31/23/31	MT
Needham Adjusts Price Target on Pacira BioSciences to $63 From $66, Maintains Buy Rating	06/23/06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Pacira BioSciences, Inc.

Equities

PCRX

US6951271005

Analyst Reco.

Filters